Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.
FDA Approves GSK’s Arexvy to Prevent Respiratory Syncytial Virus in Adults Aged 50-59 with Increased Risk
Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.